MRI BLOG

Wednesday, January 27, 2010

New Blood Pool Contrast Agent - Ablavar

......................................................................................................

There have been quite a number of discussions recently on "Ablavar" - the newly FDA-approved blood pool contrast agent for use in magnetic resonance angiography (MRA) to evaluate aortoilac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD). Is anyone out there who has experience in the clinical use of Ablavar willing to share with us the safety and efficacy of this blood pool contrast agent? MRA images using Ablavar, if available, will be awesome and most welcome. The images can be sent to me through email and I'll post them up here for sharing.

Illustrated below is one of the clinical examples of the applicaton of blood pool contrast agent from www.bloodpoolagents.com:

(Click on image to enlarge)

More information on Blood Pool Agents.

Tags: Ablavar, Gadofosveset trisodium, Gd, MRA, AIOD, PVD, blood pool contrast agent, aneurysm spurium, thrombosis

Reference:
Goyen M et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.Radiology. 2005;236(3):825-833.

Rapp JH et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. Radiology. 2005;236(1):71-78.

Perreault P et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial.Radiology. 2003;229(3):811-820.

DISCLOSURE

......................................................................................................

Funding Source

This blog is hosted by Blogger, a free publishing tool from Google, for sharing thoughts & ideas on Magnetic Resonance Imaging with the MRI community. I’ve to pay out of my own pocket at a later date when the volume of data of this site exceeds the free storage provided by Google. I take my own time to post here and read other sites; and am not paid by anybody to do this.

Advertising Policy

This site is developed basically for knowledge and information sharing and will not accept advertisement or sponsorship of any sort at this stage.

Confidentiality Policy

Reader’s privacy is highly respected. Information on internet browser used by readers, time of visit & pages read, internet service provider and IP address collected from the visitors will not be disclosed to other parties. These data will ONLY be used for statistics and site improvement purpose. Email address provided by individual readers will also ONLY be used by the author of this site.

This blog is open to the public and is therefore freely accessible by all internet users. Readers are encouraged to express their comments to any entries posted in this blog. Modification or removal of the comments posted is possible by notifying the author of this site through "CONTACT ME" near the right upper corner of this blog.

Link Exchange Disclaimer

Links to other sites are for information only and this site accepts no responsibility or liability for access to, or the material on, any site which is linked from or to this site.

I will update any changes to the above here in this post, which can be found in the entry labelled with "DISCLOSURE".

Wednesday, January 20, 2010

T1 Values in Infarcted & Noninfarcted Myocardium for Magnevist & MultiHance

Tags: Relaxation time, T1, Inversion time, TI, null point, Gadopentetate, Gadobenate, Magnevist, MultiHance, infarcted myocardium, noninfarcted myocardium

Source:

Schlosser et al. Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate. Radiology (2005) vol. 236 (3) pp. 1041-6.

Null Point for Late Gd Enhancement

Tags: Inversion Time, TI, Gadolinium, Late Gadolinium Enhancement, LGE

Source:

Yamrozik JA, Meister J, Geetha R, et al. Combined effects of Gadolinum dosage and delay on myocardial nulling. Journal of Cardiovascular Magnetic Resonance (2007) 9, 477–491.